Biotie regains rights to develop PDE10 inhibitors for CNS disorders
Biotie announced that it will regain rights to compounds relating to PDE10 inhibition for the treatment of CNS disorders, including schizophrenia. The compounds were the subject of a four-year collaboration with Wyeth (which was acquired by Pfizer in 2009) which started in 2006 and which yielded several promising PDE10 inhibitors that have demonstrated activity in pre-clinical models of schizophrenia.
Timo Veromaa, Chief Executive Officer of Biotie commented, "We are excited about PDE10 as a novel target for the treatment of schizophrenia and other disorders of the central nervous system. We have had a succesful research collaboration with Wyeth, and then Pfizer, and together we have generated supportive data for this class. We are now in a position to pursue novel clinical candidates going forward."
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.